Expert Analysis

Management of Antiretroviral-Naive Patients

Source: CCO Independent Conference Coverage of the 2009 Conference on Retroviruses and Opportunistic Infections*

*CCO is an independent medical education company that provides state-of-the-art medical information to healthcare professionals through conference coverage and other educational programs.

Management of Antiretroviral-Naive Patients

Faculty:

Joel E. Gallant, MD, MPH
W. David Hardy, MD
Kathleen E. Squires, MD

CREDIT INFORMATION

Release Date: March 26, 2009

Expiration Date: March 25, 2010

Physicians: maximum of 1.75 AMA PRA Category 1 Credits™

Registered Nurses: 1.9 Nursing contact hours

Pharmacists: 1.9 contact hours (0.19 CEUs)

Status: The activity is not currently available for credit.

Learning Objectives

Upon completion of this activity, participants should be able to:

Summarize new findings on the clinical impact of initiating antiretroviral therapy at higher CD4+ cell counts
Discuss recent data on the association between abacavir use and cardiovascular disease risk
Describe new results on proximal renal tubular dysfunction in patients receiving tenofovir-containing antiretroviral therapy
Articulate the latest data on key factors associated with patient adherence to antiretroviral therapy
Cite outcomes from recent studies investigating the efficacy of antiretroviral treatment strategies in resource-limited settings, including methods to prevent mother-to-child HIV-1 transmission

Topics covered include:

NA-ACCORD and ART-CC: New Data From Cohort Studies Regarding the Optimal Timing of Antiretroviral Initiation
Limited-Duration Antiretroviral Therapy for Acute HIV-1 Infection
Abacavir Exposure Associated With Increased MI Risk in D:A:D, French Hospital Database Cohort, and STEAL Trials
No Association Between Abacavir Use and CVD Risk in a Meta-analysis of 5 ACTG Trials
Comparative Analysis of Data Sets Evaluating CVD Risk With Abacavir
Abacavir Use and Platelet Aggregation and Biomarkers of Inflammation and Endothelial Activation
Tenofovir Use and Proximal Renal Tubular Dysfunction
STARTMRK: Subgroup Analysis of Week 48 Efficacy of Raltegravir vs Efavirenz in Treatment-Naive Patients
ARTEMIS: Week 96 Superiority of Darunavir/Ritonavir vs Lopinavir/Ritonavir due to Reduced Incidence of Virologic Failure
OCTANE: Nevirapine vs Lopinavir/Ritonavir Following Single-Dose Nevirapine for the Prevention of Mother-to-Child HIV-1 Transmission
Factors Associated With Improved Antiretroviral Treatment Adherence
New Pharmacokinetic Enhancing Agents
Efficacy of HAART in Sub-Saharan Africa

Abstract

Click here to view abstract

Disclaimer: The materials published on the Clinical Care Options Sites reflect the views of the reviewers or authors of the CCO material, not those of Clinical Care Options, LLC, the CME provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.